RxDoctor Payments Data

Joel Reginelli, MD

Cardiovascular Disease · Cincinnati, OHNPI 1780687335

Payments from drug & device makers

$23,875in general payments, 2019–2025

Across 32 payments — averaging $746.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$15K
  • Medtronic$5K
  • Asahi Intecc USA, Inc.$3K
  • Bard Peripheral Vascular, Inc.$340
  • Philips North America LLC$177
  • AstraZeneca$151
  • plus $96 from 5 others

What the payments were for

  • Speaking & faculty fees$8,32093%
  • Travel & lodging$350%
  • Food & beverage$5556%

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,875 in reported general payments places this provider in the 80th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$145,660
Medicare patients
1,041
Services billed
1,931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban529$607,447
XareltoRivaroxaban202$227,909
Repatha SureclickEvolocumab206$217,458
EntrestoSacubitril/Valsartan111$130,428
JardianceEmpagliflozin79$85,177
Praluent PenAlirocumab51$27,692
FarxigaDapagliflozin Propanediol24$16,018
Metoprolol Succinate629$8,375
Ezetimibe360$6,914
Atorvastatin Calcium660$5,344
Rosuvastatin Calcium477$4,843
SavaysaEdoxaban Tosylate30$4,713
Ranolazine ErRanolazine32$2,889
ClopidogrelClopidogrel Bisulfate193$2,131
Losartan Potassium249$2,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$607,447529 claims
AstraZenecaFarxiga$151$16,01824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →